Last reviewed · How we verify

NCT06033144: PRESTIO

Prevalence of Tapia's Syndrome in Weaning Unit

Recruiting now Last updated 15 September 2025
What this trial tests

trial testing Diagnosis of Tapia's Syndrome in Tapia's Syndrome in 247 participants. Currently enrolling.

Timeline
7 April 2023
Primary endpoint
7 November 2025
7 April 2027

Quick facts

Lead sponsorHopital Forcilles
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment247
Start date7 April 2023
Primary completion7 November 2025
Estimated completion7 April 2027
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hopital Forcilles

Who can join

18 and older, any sex, with Tapia's Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tapia syndrome is a rare and poorly understood pathology. It is defined by a concomitant attack of the recurrent (branch of X) and hypoglossal (XII) nerves of peripheral or central origin. It is characterized by the paralysis of a vocal cord and the ipsilateral half of tongue. This damage is most often unilateral but it can also be bilateral. It results in dysphonia and swallowing disorders. Tapia syndrome is a rare and poorly understood pathology. To date, less than 100 cases have been described in the literature. Previous works are mainly case reports and literature reviews. No prevalence study has been performed to date. Furthermore, disagreements persist regarding the semiology. Indeed, the involvement of the soft palate is not always described.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hopital Forcilles trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06033144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing